What Abbott's Quarter ended Sep 30, 2026 10-Q says: 6 signals
Abbott filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses bookings decline, debt refinancing and margin pressure.
Public (ABT)Medical Equipment Manufacturing10,000+ employeesabbott.comLinkedIn
Get Abbott's live signals in Claude or ChatGPT, or by API
What changed at Abbott this week? Use Autobound signals for abbott.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 17
Source: Autobound Signal API · 112 signals tracked for Abbott · updated
10-Q · latest 10
What Abbott's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 6 signals
Abbott plans to separate Global Nutrition business into an independent public company by end of 2027
In October 2026, Abbott announced its intention to separate its Nutrition business, including brands like Similac, PediaSure, and Ensure, into an independent publicly traded company via a tax-free distribution.
Issued $20.0 billion long-term debt to fund Exact Sciences acquisition
Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion, funded primarily through the issuance of $20.0 billion of long-term debt in March 2026.
$20B
issuance of long-term debt to fund the Exact Sciences acquisition
Abbott launched SimpleScreen CRC and secured FDA approvals for TactiFlex Duo and Libre Duo in 2026
Abbott launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test, in September 2026 and secured FDA approval for TactiFlex Duo and Libre Duo.
pulsed field ablationradiofrequencybiowearable sensor
Gross profit margin compressed to 50.3% in Q3 2026 due to amortization and costs
Gross profit margin percentage declined to 50.3% for Q3 2026 from 51.7% in Q3 2025, driven by higher intangible amortization from the Exact Sciences acquisition, increased costs, and unfavorable foreign exchange.
50.3%
gross profit margin percentage for the third quarter of 2026
Rapid and Molecular Diagnostics sales fell 5.4% on lower respiratory test demand
Rapid and Molecular Diagnostics segment sales decreased 5.4% excluding foreign exchange in the first nine months of 2026 due to lower demand for respiratory virus tests.
-5.4%
sales decrease excluding foreign exchange
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 5 signals
Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion on March 23, 2026
Abbott completed the acquisition of Exact Sciences for approximately $20.6 billion, funding it primarily through $20.0 billion of long-term debt and adding Cologuard, Oncotype DX, and Cancerguard to its diagnostics portfolio.
$20.6B
acquisition of Exact Sciences Corporation
Abbott issued $20.0 billion of long-term debt in March 2026 for acquisition
Abbott funded the acquisition of Exact Sciences primarily through the issuance of $20.0 billion of long-term debt in March 2026.
$20B
issuance of long-term debt in March 2026
Abbott secured CE Mark for Libre Duo dual glucose-ketone biowearable sensor in May 2026
Abbott announced it secured CE Mark for Libre Duo, its dual glucose-ketone biowearable sensor, in May 2026.
biowearable sensor
Gross profit margin percentage declined to 52.5% from 52.7% on higher costs and amortization
Gross profit margin percentage fell to 52.5% for the second quarter and first six months of 2026 compared to 52.7% in 2025 due to higher intangible amortization and higher costs.
52.5%
gross profit margin percentage for the second quarter and first six months of 2026
Beginning in 2026, Abbott aggregated its Rapid Diagnostics, Molecular Diagnostics, and Point of Care units into Rapid and Molecular Diagnostics, and moved its Amplatzer Amulet business into Electrophysiology.
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 6 signalsSEC EDGAR
Showing 10 of 17 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Abbott earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Separating nutrition business into independent public company by late 2027Plans to separate its nutrition segment into an independent publicly traded pure-play company with $8.5B in annual sales and 16,000 employees. The transaction is targeted for completion by late 2027 via a tax-free distribution to shareholders. Post-separation, the remaining medical business expects sales growth to accelerate by 50 to 100 bps and gross margins to improve by over 200 bps. | |
| Sales grew 7% and adjusted EPS rose 9% in Q3Third quarter sales increased 7% on a comparable basis, accelerating from first half trends. Adjusted EPS of $1.42 grew 9% year-over-year, while operating margin expanded 40 basis points to 23.4% and gross margin reached 57.2%. | |
| Daniel Salvadori appointed Chief Executive Officer of new nutrition spinoffAppointed Daniel Salvadori as Chief Executive Officer of the newly announced nutrition spinoff entity. Salvadori currently serves as Executive Vice President and Group President of Established Pharmaceuticals and Nutrition Products. He will lead the executive management team navigating the separation process. | |
| July cybersecurity event slowed cancer diagnostics and reduced sales growthA cybersecurity incident in July caused system disconnections across hospital accounts, directly reducing quarterly sales growth in cancer diagnostics by approximately one percentage point. Connected health accounts reverted to manual faxes and emails for 7 to 10 days before digital connectivity could be verified and reestablished. | |
| WIC contract wins expand pediatric nutrition market leadershipSecured WIC program contract wins across the United States earlier in the year, helping regain overall market leadership across both WIC and non-WIC pediatric segments. Pediatric nutrition sales grew 9% overall and 11% in the US, driven partly by this expansion in public healthcare procurement volume. | |
| Partnering on blood-based colorectal cancer screening test commercial rolloutLaunched a first blood-based colorectal cancer screening test developed alongside an external partner to complement stool-based screening. The diagnostic test features a higher ASP than existing alternatives, with commercialization and pricing strategies being structured jointly with payers and healthcare systems. |
Signal API · MCP
Track Abbott with the Signal API
One POST /v1/companies/enrich call with abbott.com returns Abbott 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbott.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Abbott 10-Q
When did Abbott file its latest 10-Q?
What did Abbott disclose in its latest 10-Q?
What did Abbott say on its recent earnings calls?
Where can I read Abbott's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .